High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder

Biological Psychiatry

Volumn 53, Issue 2, 2003, Pages 157-165

  Breunis, M Nadine ^a   Kupka, Ralph W ^b   Nolen, Willem A ^b   Suppes, Trisha ^c   Denicoff, Kirk D ^d   Leverich, Gabriele S ^d   Post, Robert M ^d   Drexhage, Hemmo A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

B cells; Bipolar disorder; NK cells; sIL 2R; T cells

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CELL MARKER; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; BIPOLAR DISORDER; CELL ASSAY; CELL COUNT; CIRCULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC PROCEDURE; FLUORESCENCE; HUMAN; HUMAN CELL; MANIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SOLUBILITY; T LYMPHOCYTE ACTIVATION; TIME;

EID: 12244286806     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01452-X     Document Type: Article

References (52)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;American Psychiatric Press, Washington, DC.
2. Aust G., Lehmann I., Heberling H.J. Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease. Exp Clin Endocrinol Diabetes. 104:1996;50-58.
3. Bayer A.L., Baliga P., Woodward J.E. Transferrin receptor in T cell activation and transplantation. J Leukoc Biol. 64:1998;19-24.
4. Cover H., Irwin M. Immunity and depression Insomnia, retardation, and reduction of natural killer cell activity . J Behav Med. 17:1994;217-223.
5. Darko D.F., Lucas A.H., Gillin J.C., Risch S.C., Golshan S., Hamburger R.N., et al. Cellular immunity and the hypothalamic-pituitary axis in major affective disorder A preliminary study . Psychiatry Res. 25:1988;1-9.
6. de Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 19:1998;269-301.
7. Dong C., Flavell R.A. Th1 and Th2 cells. Curr Opin Hematol. 8:2001;47-51.
8. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomathology and responsiveness to risperidone treatment. Mediators Inflamm. 10:2001;109-115.
9. Esterling B.A., Kiecolt-Glaser J.K., Bodnar J.C., Glaser R. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. Health Psychol. 13:1994;291-298.
10. Evans D.L., Folds J.D., Petitto J.M., Golden R.N., Pedersen C.A., Corrigan M., et al. Circulating natural killer cell phenotypes in men and women with major depression Relation to cytotoxic activity and severity of depression . Arch Gen Psychiatry. 49:1992;388-395.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition: SCID-I/P (version 2.0). 1996;Biometrics Research Department, New York.
12. Gaughran F., O'Neill E., Sham P., Daly R.J., Shanahan F. Soluble interleukin 2 receptor levels in acute and stable schizophrenia. Schizophr Res. 52:2001;143-144.
13. Gollob K.J., Dutra W.O., Coffman R.L. Early message expression of interleukin-4 and interferon-gamma, but not of interleukin-2 and interleukin-10, reflects later polarization of primary CD4+ T cell cultures. Eur J Immunol. 26:1996;1565-1570.
14. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission Effects of confounding factors and diagnosis . J Psychiatr Res. 33:1999;407-418.
15. Heiser P., Dickhaus B., Schreiber W., Clement H.W., Hasse C., Hennig J., et al. White blood cells and cortisol after sleep deprivation and recovery sleep in humans. Eur Arch Psychiatry Clin Neurosci. 250:2000;16-23.
16. Hornig M., Goodman D.B., Kamoun M., Amsterdam J.D. Positive and negative acute phase proteins in affective subtypes. J Affect Disord. 49:1998;9-18.
17. Irwin M. Immune correlates of depression. Adv Exp Med Biol. 461:1999;1-24.
18. Jung W., Irwin M. Reduction of natural killer cytotoxic activity in major depression Interaction between depression and cigarette smoking . Psychosom Med. 61:1999;263-270.
19. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S., et al. Plasma concentrations of interleukin-1β, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor α of depressed patients in Japan. Neuropsycobiology. 43:2001;59-62.
20. Kanba S., Manki H., Shintani F., Ohno Y., Yagi G., Asai M. Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode. Psychol Med. 28:1998;481-484.
21. Kupka R.W., Hillegers M.H.J., Nolen W.A., Breunis N., Drexhage H.A. Immunological aspects of bipolar disorder. Acta Neuropsychiatrica. 12:2000;86-90.
22. Kupka R.W., Nolen W.A., Altshuler L.L., Denicoff K.D., Frye M.A., Leverich G.S., et al. The Stanley Foundation Bipolar Network Part 2. Preliminary summary of demographics, course of illness, and response to novel treatments . Br J Psychiatry. 178:(suppl 41):2001;S177-S183.
23. Kupka R.W., Nolen W.A., Post R.M., McElroy S.L., Altshuler L.L., et al. High rate of autoimmune thyroiditis in bipolar disorder Lack of association with lithium exposure . Biological Psychiatry. 51:2002;305-311.
24. Leverich G.S., Nolen W.A., Rush A.J., McElroy S.L., Keck P.E., Denicoff K.D., et al. The Stanley Foundation Bipolar Outcome Network I. Longitudinal Methodology. J Affect Disorders. 67:2001;33-44.
25. Maes M. Evidence for an immune response in major depression A review and hypothesis . Prog Neuropsychopharmacol Biol Psychiatry. 19:1995;11-38.
26. Maes M. The immune pathophysiology of major depression. Honig A., Van Praag H.M. Depression: Neurobiological, Psychopathological and Therapeutic Advances. 1997;197-215 Wiley & Sons, London.
27. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania Effects of neuroleptics and mood stabilizers . J Psychiatr Res. 29:1995;141-152.
28. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., et al. Acute phase proteins in schizophrenia, mania and major depression Modulation by psychotropic drugs . Psychiatry Res. 66:1997;1-11.
29. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci. 244:1995;325-329.
30. Maes M., Van de Vyvere J., Vandoolaeghe E., Bril T., Demedts P., Wauters A., et al. Alterations in iron metabolism and the erythron in major depression Further evidence for a chronic inflammatory process . J Affect Disord. 40:1996;23-33.
31. Maisel A.S., Harris T., Rearden C.A., Michel M.C. Beta-adrenergic receptors in lymphocyte subsets after exercise Alterations in normal individuals and patients with congestive heart failure . Circulation. 82:1990;2003-2010.
32. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentration in major depression and multiple sclerosis. Eur Neuropsychopharmacol. 11:2001;203-208.
33. Mizruchin A., Gold I., Krasnov I., Livshitz G., Shahin R., Kook A.I. Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system. J Neuroimmunol. 101:1999;201-204.
34. Muller N., Hofschuster E., Ackenheil M., Mempel W., Eckstein R. Investigations of the cellular immunity during depression and the free interval Evidence for an immune activation in affective psychosis . Prog Neuropsychopharmacol Biol Psychiatry. 17:1993;713-730.
35. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia An integrative view . Ann NY Acad Sci. 917:2000;456-467.
36. Natelson B.H., LaManca J.J., Denny T.N., Vladutiu A., Oleske J., Hill N., et al. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. Am J Med. 105:1998;43S-49S.
37. Post R.M., Nolen W.A., Kupka R.W., Denicoff K.D., Leverich G.S., Keck P.E., et al. The Stanley Foundation Bipolar Network Part 1. Rationale and methods . Br J Psychiatry. 178:(suppl 41):2001;S169-S176.
38. Rapaport M.H. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 32:1994;149-156.
39. Rapaport M.H., Guylai L., Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 33:1999;335-340.
40. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med. 60:1998;283-289.
41. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J Affect Disord. 52:1999;1-10.
42. Rybakowski J.K. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry. 33:2000;159-164.
43. Schleifer S.J., Keller S.E., Bartlett J.A. Depression and immunity Clinical factors and therapeutic course . Psychiatry Res. 85:1999;63-69.
44. Shek P.N., Sabiston B.H., Buguet A., Radomski M.W. Strenuous exercise and immunological changes A multiple-time-point analysis of leukocyte subsets, CD4/CD8 ratio, immunoglobulin production and NK cell response . Int J Sports Med. 16:1995;466-474.
45. Suppes T., Leverich G.S., Keck P.E., Nolen W.A., Denicoff K.D., Altshuler L.L., et al. The Stanley Foundation Bipolar Outcome Network II. Demographics and illness characteristics of the first 261 patients . J Affect Disord. 67:2001;45-49.
46. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res. 47:2001;13-25.
47. Tsai S.Y., Chen K.P., Yang Y.Y., Chen C.C., Lee J.C., Singh V.K., et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 45:1999;989-994.
48. Van Tits L.J., Michel M.C., Grosse-Wilde H., Happel M., Eigler F.W., Soliman A., et al. Catecholamines increase lymphocyte beta 2-adrenergic receptors via beta 2-adrenergic, spleen-dependent process. Am J Physiol. 258:1990;E191-202.
49. Waldner C., Mongini C., Alvarez E., Roig I., Hajos S.E. Inhibitory activity of soluble IL-2R in sera, ascites and culture supernatants from murine leukaemic cells. Scand J Immunol. 40:1994;308-316.
50. Wiltrout R.H. Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol Rev. 174:2000;63-76.
51. Wrona D., Jurkowski M.K., Trojniar W., Staszewska M., Tokarski J. Electrolytic lesions of the lateral hypothalamus influence peripheral blood NK cytotoxicity in rats. J Neuroimmunol. 55:1994;45-54.
52. Yovel G., Sirota P., Mazeh D., Shakhar G., Rosenne E., Ben-Eliyahu S. Higher natural killer cell activity in schizophrenic patients The impact of serum factors, medication, and smoking . Brain Behav Immun. 14:2000;153-169.